瑞舒伐他汀治疗对代谢综合征患者的影响

目的：探讨口服不同剂量的瑞舒伐他汀治疗对代谢综合征患者血脂、血管内皮功能及炎性因子的影响。方法整群选择该院在2012年6月—2015年3月所收治代谢综合征患者122例作为研究对象，按照入院顺序随机分为两组，观察组60例，服用瑞舒伐他汀20 mg 每晚1次。对照组62例，采取常规治疗。观察12周，监测相关指标的变化。结果两组治疗12周后较治疗前：总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、内皮素(ET)、高敏C反应蛋白(hs-CRP)均有明显降低，治疗12周后，观察组的 TC (5.4±0.6)mmol/L、TG (2.6±0.4)mmol/L、HDL-C (1.07±0.2)mmol/L、ET(46.8±4.7)ng/L、hs-CRP(25.7±4.8)mg/L明显较对照组的TC(5.6±0.6)mmol/L、TG(2.8±0.5)mmol/L、HDL-C(1.12±0.2)mmol/L、ET(54.6±5.3)ng/L、hs-CRP(30.6±5.2)mg/L更低，差异有统计学意义(P<0.05)；观察组的CK (136.1±61.2)U/L、AST(23.2±7.9)U/L、ALT(24.9±8.0)U/L与对照组的CK(136.5±58.7)U/L、AST(22.1±8.1)U/L、ALT(23.2±8.2)U/L相比，差异无统计学意义(P>0.05)。结论瑞舒伐他汀对代谢综合征患者均有调脂、抗炎、改善血管内皮功能的作用，其大剂量有更强的调脂、抗炎、改善血管内皮功能的作用，但肌损害、肝损害的副作用并未增加。

The Effects of Different Doses of Oral Rosuvastatin Treatment on Patients with Metabolic Syndrome

Objective To observe effects of different doses of oral rosuvastatin treatment on blood lipids, vascular endothe-lial function and inflammatory factors in patients with metabolic syndrome. Methods Group selection choose 122 cases of patients with metabolic syndrome,were randomly divided into two groups: observation group of 60 cases, taking rosuvastatin 20mg one time a night. Control group 62 cases, and taking rosuvastatin 10mg one time a night.12 weeks observation, moni-toring the change of relevant indicators. Results 12 weeks after treatment than before treatment: total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C), endothelin (ET), high-sensitivity C-reactive protein (hs-CRP) were have significantly reduced after 12 weeks of treatment, TC observation group (5.4±0.6) mmol/L, TG (2.6±0.4) mmol/L, HDL-C (1.07 ± 0.2) mmol/L, ET(46.8±4.7) ng/L, hs-CRP(25.7 ± 4.8) mg/L significantly higher than the TC in the control group (5.6 ± 0.6) mmol/L, TG (2.8±0.5) mmol/L, HDL-C (1.12±0.2) mmol/L, ET (54.6±5.3) ng/L, hs-CRP (30.6 ± 5.2) mg / L lower, the difference was statistically significant (P<0.05); CK observation group (136.1±61.2) U/L, AST (23.2 ± 7.9) U / L, ALT (24.9 ± 8.0) U/L and control group (136.5±58.7) U/L, AST (22.1±8.1) U/L, ALT (23.2±8.2) U/L also no significant dif-ference, the difference was not statistically significant (P> 0.05). Conclusion Different doses of oral rosuvastatin treatment possessed the effects of lipid-lowering,anti-inflammatory and improving endothelial function in patients with metabolic syn-drome.and high-dose of oral rosuvastatin treatment had the stronger effects of lipid-lowering,anti-inflammatory and improv-ing endothelial function, but it did not increase the side effects of muscle damage and liver damage.